BARCELONA, Spain--(BUSINESS WIRE)--At ECCMID, the annual European Conference on Clinical Microbiology and Infectious Diseases, Cambridge UK-based Phico Therapeutics presented new data on the rapid bactericial activity of its lead compound against MRSA. PT1.2 belongs to a new class of antibacterial proteins called SASPs that act by binding to bacterial DNA and halting replication and gene expression, resulting in rapid cell death. Phico Therapeutics now intends to take PT1.2 into clinical trials using its unique delivery platform technology called SASPject™
